Switzerland

Back to Search

International Partner Search

Innovation & Technology Offer

Active RiboNucleic Acid selection and analysis KIT

Country of Origin: Italy
Reference Number: TOIT20170829001
Publication Date: 29 August 2017

Summary

An Italian startup, specialised in RNA (RiboNucleic Acid) analysis, delivers smart solutions for better gene expression studies. The company offers technologies to assess translational control of gene expression and translatome associated biomarkers.
The uniqueness of the core technology resides in the selective isolation of actively translated mRNAs. Kit for better ribosome profiling are available. The company is looking for commercial agreements, licencing and research collaborations.

Description

The Italian company, a start up born in 2014 and managed by a young team of PhD's ("Doctors on Philosophy") with academic experience in biomolecular science and material chemistry, is located in a scientific science park and specialised in RNA (RiboNucleic Acid) analysis and delivering of smart solutions for better gene expression studies. It offers a technology for better ribosome profiling studies, by means of an antibody-free and tag-free pull-down approach to capture only active ribosomes.

Typical applications are:
- measurements of gene expression at the level of actual protein synthesis
- assay on drugs acting at the translatome level
- discovery of new prognostic biomarkers in cancer and neurodegenerative diseases
- speed up the validation of existing biomarkers in cancer

Features of the technology:
1) 120 min prep. – and no more polysome profile (2 days)
2) easy-to-use
3) extraction of ribosome protected RNA fragments only from active ribosomes
4) antibody free
5) basic kit composition: magnetic beads, active polymer, buffer 1, buffer 2, buffer 3
6) custom kit availability

The company is looking for commercial agreement, research cooperation agreements and license agreement.
In case of commercial agreement the partner should be a biological laboratory that will be provided with kits for biological testing.

In case of research cooperation, the partner should be a biological laboratory using the kits for testing biological applications.

In case of license agreement, the partner should be an industry working in biological pharmaceutical sector and it should use the licence to produce complementary technologies
Image

Image

Advantages and Innovations

Innovations:
1) fast protocol (10x). No more 24 hours of polysome profile required as for other existing products;
B) it works reliably with low amounts of input material. Less than 10^5 cells are required for isolation of active ribosome protected fragments;
C) it can be easily and rapidly applied both in vitro and in vivo, thereby generating a global snapshot of active ribosome footprints at single nucleotide resolution. No other tolls can generate a snapshot of protein expression with such degree of
resolution and accuracy;
4) thanks to a novel method based on an original puromycin-containing molecule (patented) capable of isolating active ribosomes, the company can offer the only technology on the market able to quantify active ribosomes.

Main advantages compared to existing kits:
1) fastness: 120 min sample prep;
2) no more polysome profile (2 days);
2) easy-to-use;
3) more accurate gene expression analysis.

Stage Of Development

Available for demonstration

Stage Of Development Comment

The startup just started the Early Access Programme (EAP) for the core technology. The EAP allows innovative researchers to get first access to the novel technology. Fourteen (14) labs involved worldwide.

Requested partner

In case of commercial agreement the company is looking for biological laboratories that are interested in using the company's kits for biological testing.
The company will provide kits by courier to the laboratory and assist this latter giving hints and instructions for correct use.

In case of research cooperation, the partner should be a biological laboratory and it would use the kits for testing biological applications.

In case of license agreement, the partner should be an industry working in biological pharmaceutical sector. The company would license its know-how (in terms of patents and knowledge) to the partner, that would produce technologies complementary to those already produced by the company.

Dissemination Countries

Albania, Armenia, Argentina, Austria, Bosnia and Herzegovina, Belgium, Bulgaria, Brazil, Belarus, Canada, Switzerland, Chile, Cameroon, China, Cyprus, Czech Republic, Germany, Denmark, Estonia, Egypt, Spain, Finland, France, Georgia, Greece, Croatia, Hungary, Indonesia, Ireland, Israel, India, Iceland, Italy, Jordan, Japan, South Korea, Lithuania, Luxembourg, Latvia, Moldova, Montenegro, Macedonia, The former Yugoslav Republic of, Malta, Mexico, Netherlands, Norway, New Zealand, Peru, Poland, Portugal, Paraguay, Romania, Serbia, Russia, Sweden, Singapore, Slovenia, Slovakia, Tunisia, Turkey, Taiwan, Ukraine, United Kingdom, USA, Vietnam

Contact Profile Owner